Evidence map›Paper›PMID 37794108›Full record

ArticleScientific reports2023

Down regulation of Cathepsin W is associated with poor prognosis in pancreatic cancer.

Fatemeh Khojasteh-Leylakoohi, Reza Mohit, Nima Khalili-Tanha, Alireza Asadnia, Hamid Naderi, Ghazaleh Pourali, Zahra Yousefli, Ghazaleh Khalili-Tanha, Majid Khazaei, Mina Maftooh and 10 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Unusual case ofFrontiers in cellular and infection microbiology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Thyroid cancer prognostic biomarker ARL4A and its relationship with immune infiltration.International journal of clinical and experimental pathology · 2024
    Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 6 countries.

Fatemeh Khojasteh-Leylakoohi *Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Reza Mohit *Department of Anesthesia, Bushehr University of Medical Sciences, Bushehr, Iran.
Nima Khalili-Tanha *Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Alireza AsadniaMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamid Naderi *Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Ghazaleh PouraliMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Zahra YousefliMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Ghazaleh Khalili-TanhaMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid KhazaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mina MaftoohMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammadreza NassiriRecombinant Proteins Research Group, The Research Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
Seyed Mahdi HassanianMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid Ghayour-MobarhanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Gordon A FernsBrighton and Sussex Medical School, Division of Medical Education, Falmer, Brighton, BN1 9PH, Sussex, UK.
Soodabeh ShahidsalesCancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Alfred King-Yin LamPathology, School of Medicine and Dentistry, Griffith University, Gold Coast Campus, Gold Coast, QLD, 4222, Australia.
Elisa GiovannettiDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam U.M.C., VU. University Medical Center (VUMC), Amsterdam, The Netherlands.
Elham NazariMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. NazariE4001@mums.ac.ir.
Jyotsna BatraFaculty of Health, School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane, 4000, Australia.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. avana@mums.ac.ir.
Mashhad University of Medical Sciences · IRAmsterdam UMC Location VUmc · NLBrighton and Sussex Medical School · GBBushehr University of Medical Sciences · IRFerdowsi University of Mashhad · IRGriffith University · AUTranslational Research Institute · AUUniversity of Karbala · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is associated with a very poor prognosis. Therefore, there has been a focus on identifying new biomarkers for its early diagnosis and the prediction of patient survival. Genome-wide RNA and microRNA sequencing, bioinformatics and Machine Learning approaches to identify differentially expressed genes (DEGs), followed by validation in an additional cohort of PDAC patients has been undertaken. To identify DEGs, genome RNA sequencing and clinical data from pancreatic cancer patients were extracted from The Cancer Genome Atlas Database (TCGA). We used Kaplan-Meier analysis of survival curves was used to assess prognostic biomarkers. Ensemble learning, Random Forest (RF), Max Voting, Adaboost, Gradient boosting machines (GBM), and Extreme Gradient Boosting (XGB) techniques were used, and Gradient boosting machines (GBM) were selected with 100% accuracy for analysis. Moreover, protein-protein interaction (PPI), molecular pathways, concomitant expression of DEGs, and correlations between DEGs and clinical data were analyzed. We have evaluated candidate genes, miRNAs, and a combination of these obtained from machine learning algorithms and survival analysis. The results of Machine learning identified 23 genes with negative regulation, five genes with positive regulation, seven microRNAs with negative regulation, and 20 microRNAs with positive regulation in PDAC. Key genes BMF, FRMD4A, ADAP2, PPP1R17, and CACNG3 had the highest coefficient in the advanced stages of the disease. In addition, the survival analysis showed decreased expression of hsa.miR.642a, hsa.mir.363, CD22, BTNL9, and CTSW and overexpression of hsa.miR.153.1, hsa.miR.539, hsa.miR.412 reduced survival rate. CTSW was identified as a novel genetic marker and this was validated using RT-PCR. Machine learning algorithms may be used to Identify key dysregulated genes/miRNAs involved in the disease pathogenesis can be used to detect patients in earlier stages. Our data also demonstrated the prognostic and diagnostic value of CTSW in PDAC.

Indexed as

Carcinoma, Pancreatic DuctalMicroRNAsPancreatic NeoplasmsBiomarkersBiomarkers, TumorCathepsin WDown-RegulationGene Expression Regulation, NeoplasticHumansPrognosisBiomarkersBiomarkers, TumorCathepsin WMicroRNAs

Identifiers

PMID37794108
PMCPMC10551021
OpenAlexW4387335391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.